Procyon Corporation (PCYN) fair value: what the stock is really worth
As of Sep 15, 2026: fair value of Procyon Corporation $0.14, price $0.26, upside -46.2%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Procyon Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0013 – $0.9500 · fair‑value band $0.1000 – $0.1400 · the $0.2600 price screens above the $0.1400 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Procyon in your weekly email
Every Wednesday you see whether Procyon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States.
Show more
Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States. It provides AMERIGEL, an advanced skin and wound care products, including hydrogel wound dressing, post op surgical kits, saline wound washes, and care and barrier lotions; HELIX3 Bioactive Collagen products, such as collagen powder, gel, and matrix; and calcium alginate dressing, foam dressing, amerx gauze dressing, hyrdocolloid dressing, as well as wound care kits, including calcium alginate, collagen matrix, collagen powder, foam, hydrogel, and rolled gauze wound care kits under the AMERX brand. The company also offers AMERIGEL hand sanitizer; EXTREMIT-EASE compression garment products; Advantagen, a surgical collagen powder that promotes wound closure and reduces the potential for surgical site infection; calcium alginate, foam, and gauze dressings; retention tapes; and helix collagen gel. It sells its products to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, physicians, and other health care practitioners; and retail customers through distributors, and direct and internet sales, as well as through independent and retail chain drug stores. Procyon Corporation was incorporated in 1987 and is based in Oldsmar, Florida.
Stock analysis
Procyon Corporation (PCYN) currently trades at $0.2600, while our model-based Fair Value estimate is $0.1400, implying the stock looks roughly 85.7% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.5300 per share, and 1 of the 10 models we run sit above the $0.2600 price.
Bear case: the Earnings-Based group reads lowest at $0.0300, and 9 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1000 (bear) to $0.1400 (bull), the price of $0.2600 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Procyon Corporation reported revenue of $6.7M in FY2025 versus $4.7M in FY2021, a compound +9.0%/yr. Reported net income was $33.9K in FY2025, compounding −53.0%/yr from FY2021.
Key figures
Market cap $2.2M · P/S ratio 0.33 · EPS (TTM) $−0.0400 · Net margin 0.5% · Return on equity −13.9% · Return on assets (EBIT) −4.8% · Operating margin 0.6% · Revenue (TTM) $5.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 7% below its 52-week high and 155% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −46%, PCYN screens richer than that median.
Fair Value models
Bear $0.1000Fair Value $0.1400Bull $0.1400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+33.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Start year 2020 (pandemic). Over 10 years: +9.2% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−21.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−21.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−21% vs −7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → −7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−46% · Below median
Profitability
Return on assets−4% · Bottom 25%
Net margin (TTM)−7% · Bottom 25%
Operating margin (TTM)1% · Below median
Growth and dividend
Revenue growth18% · Top 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.94× · Cheaper than median
P/S (TTM)0.44× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)88· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)97· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Procyon Corporation Fair Value". https://www.fairvalue-calculator.com/stock/PCYN
Frequently asked questions
Is Procyon Corporation (PCYN) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.1400 versus the last price from Sep 15, 2026 of $0.2600, about −46% upside (overvalued).
What is the fair value of PCYN?
Our model-based fair value for Procyon Corporation is $0.1400 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 15, 2026): $0.2600.
What is the quality score of PCYN?
Procyon Corporation has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Procyon Corporation (PCYN)?
Our model-based price target is the fair value of $0.1400 (as of Sep 23, 2026) from 10 valuation models. Cautious scenario $0.1000, optimistic scenario $0.1400. It is a calculation from audited fundamentals, not an analyst target.
What is the Procyon Corporation stock forecast for 2026?
Our models put fair value at $0.1400, about −46% upside versus the last price from Sep 15, 2026 of $0.2600 (overvalued). Cautious scenario $0.1000, optimistic scenario $0.1400. The calculation is refreshed regularly with new filings.
What is the revenue of Procyon Corporation (PCYN)?
Procyon Corporation reported trailing-twelve-month revenue of about $5.0M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Procyon Corporation (PCYN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Procyon Corporation it is $0.1400 per share (as of Sep 23, 2026), against a price of $0.2600. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Procyon Corporation stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PCYN trades above its calculated fair value: price $0.2600, fair value $0.1400, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PCYN?
No. The price is what the market pays today ($0.2600); the fair value is what the company's own numbers justify ($0.1400). For Procyon Corporation the two are $0.1200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Procyon Corporation worth?
The market values Procyon Corporation at about $2.2M (market capitalisation, as of Sep 23, 2026). Per share that is $0.2600; our models calculate a fair value of $0.1400 per share.
What do the bullish and bearish scenarios say about PCYN?
Our models span a range for Procyon Corporation: cautious scenario $0.1000, base $0.1400, optimistic $0.1400 per share (as of Sep 23, 2026, price $0.2600). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Procyon Corporation (PCYN)?
Balance-sheet figures for Procyon Corporation (as of Sep 23, 2026): return on equity −13.9%, debt of 0.06 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is PCYN from its 52-week high?
Procyon Corporation trades at $0.2600, about 7% below its 52-week high of $0.2800 and 155% above the low of $0.1020 (as of Sep 15, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1400 is for.
Which stocks are comparable to Procyon Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Procyon Corporation stock attractive at the current price?
The data as of Sep 23, 2026: price $0.2600, calculated fair value $0.1400 (−46%), Quality Score 53/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PCYN calculated?
We run Procyon Corporation through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Procyon Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Procyon Corporation (PCYN)?
The latest price we hold is from Sep 15, 2026 and stands at $0.2600. Our model-based fair value is $0.1400, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Procyon Corporation right now?
The price sits above even our optimistic bull case ($0.1400). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Procyon Corporation
How large is the market capitalisation of Procyon Corporation (PCYN)?
The market capitalisation of Procyon Corporation is $2.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Procyon Corporation (PCYN)?
The price-to-sales ratio of Procyon Corporation is 0.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Procyon Corporation (PCYN)?
Earnings per share at Procyon Corporation are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Procyon Corporation (PCYN)?
The net margin of Procyon Corporation is 0.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Procyon Corporation (PCYN)?
The return on equity (ROE) of Procyon Corporation is −13.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Procyon Corporation (PCYN)?
On an EBIT basis the return on assets of Procyon Corporation is −4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Procyon Corporation (PCYN)?
The operating margin of Procyon Corporation is 0.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Procyon Corporation (PCYN)?
Revenue at Procyon Corporation is growing +17.5% versus a year earlier (3y avg +11.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Procyon Corporation (PCYN)?
Earnings per share at Procyon Corporation are growing −82.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Procyon Corporation (PCYN) generate?
The free cash flow of Procyon Corporation is −$495K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Procyon Corporation (PCYN) carry?
The net debt of Procyon Corporation is $58.5K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Procyon Corporation in the live analysis
One click puts Procyon Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026